2b1fa47d-360a-4b4a-aa11-23bdb025b559
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 72.7583846680356
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.530
- INTERFERON_ALPHA_RESPONSE+0.530
- INTERFERON_GAMMA_RESPONSE+0.330
- PROTEIN_SECRETION+0.330
- UV_RESPONSE_DN+0.290
- COAGULATION+0.250
- ANGIOGENESIS+0.230
- HEDGEHOG_SIGNALING+0.200
- APICAL_JUNCTION+0.190
- KRAS_SIGNALING_UP+0.190
Top 10 suppressed
- MYC_TARGETS_V2-0.530
- E2F_TARGETS-0.480
- G2M_CHECKPOINT-0.420
- MYC_TARGETS_V1-0.400
- OXIDATIVE_PHOSPHORYLATION-0.350
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.350
- MTORC1_SIGNALING-0.310
- UV_RESPONSE_UP-0.290
- DNA_REPAIR-0.270
- P53_PATHWAY-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 44eb0b78-9761-4131-b831-85e765a24e6b | — | — | 0.867 |
| 2 | TCGA-CR-7392-01A-11R-2016-07 | — | — | 0.867 |
| 3 | TCGA-55-7816-01A-11R-2170-07 | — | cohortMD2 | 0.866 |
| 4 | TCGA-E9-A229-01A-31R-A157-07 | — | A | 0.859 |
| 5 | AUR-AG12-TTP1-A-1-0-R-A741-41 | — | A | 0.848 |
| 6 | GSM5359411 | — | — | 0.841 |
| 7 | SRR2016976 | — | — | 0.838 |
| 8 | R132 | — | — | 0.837 |
| 9 | TCGA-D6-6824-01A-11R-1915-07 | — | — | 0.837 |
| 10 | 1b192a49-01cb-4459-a7a7-fdebe428f386 | — | — | 0.836 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.530 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.530 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.330 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.330 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.290 | Inavolisib | — uncovered |
| COAGULATION | 0.250 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.230 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.190 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.180 | Idelalisib | — uncovered |
| COMPLEMENT | 0.170 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.170 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.140 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.130 | Inavolisib | — uncovered |
| MYOGENESIS | 0.130 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.080 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.050 | Remibrutinib | — uncovered |